Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.15)
# 3,472
Out of 4,711 analysts
106
Total ratings
30.77%
Success rate
-15.11%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Maintains: Buy | $65 → $12 | $2.23 | +438.12% | 4 | Dec 11, 2024 | |
| CYBN Cybin | Maintains: Buy | $86 | $9.61 | +794.90% | 6 | Nov 19, 2024 | |
| GHRS GH Research | Maintains: Buy | $31 → $28 | $6.85 | +308.76% | 4 | Nov 18, 2024 | |
| ATAI Atai Life Sciences | Maintains: Buy | $11 | $1.19 | +824.37% | 1 | Nov 18, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $23 | $8.49 | +170.91% | 5 | Nov 14, 2024 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 | $5.75 | +143.48% | 4 | Nov 14, 2024 | |
| CLNN Clene | Maintains: Buy | $86 → $83 | $4.40 | +1,786.36% | 5 | Nov 14, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $14 | $7.16 | +95.53% | 1 | Sep 16, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $7 | $0.34 | +1,952.79% | 6 | Aug 30, 2024 | |
| CMPS COMPASS Pathways | Maintains: Buy | $50 → $48 | $3.97 | +1,109.07% | 2 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $113 | $83.45 | +35.41% | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $1 | $0.42 | +136.63% | 4 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $11.68 | +71.23% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $154 → $164 | $135.42 | +21.10% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $4.37 | +494.97% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $21 → $17 | $5.61 | +203.03% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $16.87 | +95.61% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $310 → $305 | $146.47 | +108.23% | 19 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $36.26 | +313.68% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $22.09 | - | 2 | Jan 31, 2017 |
CervoMed
Dec 11, 2024
Maintains: Buy
Price Target: $65 → $12
Current: $2.23
Upside: +438.12%
Cybin
Nov 19, 2024
Maintains: Buy
Price Target: $86
Current: $9.61
Upside: +794.90%
GH Research
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $6.85
Upside: +308.76%
Atai Life Sciences
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $1.19
Upside: +824.37%
Zevra Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $8.49
Upside: +170.91%
Voyager Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $14
Current: $5.75
Upside: +143.48%
Clene
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $4.40
Upside: +1,786.36%
Mind Medicine (MindMed)
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $7.16
Upside: +95.53%
BioXcel Therapeutics
Aug 30, 2024
Maintains: Buy
Price Target: $7
Current: $0.34
Upside: +1,952.79%
COMPASS Pathways
Aug 2, 2024
Maintains: Buy
Price Target: $50 → $48
Current: $3.97
Upside: +1,109.07%
Jun 20, 2024
Maintains: Buy
Price Target: $107 → $113
Current: $83.45
Upside: +35.41%
Jun 13, 2024
Downgrades: Hold
Price Target: $10 → $1
Current: $0.42
Upside: +136.63%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $11.68
Upside: +71.23%
May 2, 2024
Maintains: Buy
Price Target: $154 → $164
Current: $135.42
Upside: +21.10%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $4.37
Upside: +494.97%
Apr 26, 2024
Maintains: Hold
Price Target: $21 → $17
Current: $5.61
Upside: +203.03%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $16.87
Upside: +95.61%
Feb 20, 2024
Maintains: Buy
Price Target: $310 → $305
Current: $146.47
Upside: +108.23%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $36.26
Upside: +313.68%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $22.09
Upside: -